SoftOx Solutions AS — Capital/Financing Update 2024

Jul 2, 2024

SoftOx Solution AS: Secured commitment for planned contemplated right issue

SoftOx Solution AS: Secured commitment for planned contemplated right issue

SoftOx Solutions AS hereby announces that the Company has secured commitments from selected shareholders to participate in a guarantee-consortium for a planned contemplated right issue. A majority of the shareholders participate in the guarantee-consortium. This planned contemplated right issue of NOK 22,5 million with a subscription price of NOK 0,02 will provide the company sufficient funding to plan, prepare, and run a process aiming to attract funding for a proof-of-concept, human phase 2 clinical trial for treatment of Ventilator-Associated Pneumonia (VAP).

The Board of Directors has unanimously approved the agreement and will call for an extraordinary General Meeting by the end of July 2024 to seek approval of the contemplated right share issue and the guarantee-agreement with selected shareholders. The contemplated right issue will be executed by the 24th of August 2024.

The planned share issue will give equal rights for all shareholders to participate. It will be a right issue with transferable subscription rights. Each shareholder will be issued rights to subscribe for their pro-rata amount of shares in the issue. The rights will be made tradable. Subscription of Shares that are not subscribed for, according to rights, will be granted to guarantees before others. If the Share Issue is over-subscribed, the participants in the agreement are granted the first right to subscribe for shares in the Share Issue.

For further information, please contact: 

Geir Almås, COB or Ingrid Juven, CFO of SoftOx Solutions AS, or 

Mail: ir@soft-ox.com 

Phone: Geir Almås, COB: (+47) 977 59 071 

About SoftOx Solutions AS: 

SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech/biotech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com